SABLE registry data show numerically lower 5-year mortality with belimumab vs conventional immunosuppressants in patients with SLE.
Ronald F. van Vollenhoven, MD, PhD
Advertisement
Ronald F. van Vollenhoven, MD, PhD, chair of the Department of Rheumatology and Clinical Immunology at Amsterdam UMC and director of the Amsterdam Rheumatology and Immunology Center,
Articles by Ronald F. van Vollenhoven, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Rheumatology Live
1
INSPIRE: Joint, Skin Gains Support Tildrakizumab PsA Approval: Philip Mease, MD
2
Cardiovascular Deaths, Baricitinib Data Highlight Systemic Sjögren Disease
3
GLP-1 RAs Tied to Cardiovascular, Patient-Reported Gains in Rheumatic Disease
4
Adding Tirzepatide Improves PsA Control in Obesity: Philip Mease, MD
5